Search
Tarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigationalTarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929] … Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling.
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.
Turoctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally … [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]
Products: NOVOEIGHT® 1500 UI POLVO ESTERIL PARA RECONSTITUIR A SOLUCIÓN INYECTABLEOrlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalIt was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … [A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes.
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635] … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases
Aldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. … Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalAlbumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalMavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … by a reduced number of mature neutrophils and lymphocytes.